A more disciplined approach to spending could help Meta's stock early next year, according to Rosenblatt Securities. After two blowout years, Meta's stock performance has been more subdued in 2025.
24/7 Wall St. on MSN
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback